Susan C. Fagan

Susan C. Fagan

Auto-generated profile, based on publicly available information

Susan C. Fagan

Charlie Norwood VA Medical Center, Augusta, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Journal Of Hypertension
Verified
Journal Article
Closed access
AAAhmed Alhusban
Ahmed Alhusban
Abdelrahman FoudaAbdelrahman Fouda
Abdelrahman Fouda
BPBindu Pillai
Bindu Pillai
TITauheed Ishrat
Tauheed Ishrat
SSSahar Soliman
Sahar Soliman
SFSusan C. Fagan
Susan C. Fagan
Introduction: Angiotensin II type 2 receptor (AT2R) stimulation is neuroprotective after experimental stroke. However, the therapeutic utility of AT2R stimulation has been hampered by the lack of a specific agonist with favourable bioavailability. Compound 21 (C21) – the first non-peptide AT2R agonist – offers a potential option to enhance stroke recovery. This study aimed to investigate the effect of C21 administration on early and late stroke outcomes, and the molecular mediators involved. Methods: Rats were subjected to 3 h or 90 min of middle cerebral artery occlusion (MCAO) and randomized to intraperitoneal C21 (0.03 mg/kg) or saline at reperfusion. Animals were sacrificed at 24 h or 7 days and brains were collected for molecular analysis and immunostaining, respectively. Functional outcome at days 1, 4 and 7 was assessed blindly. C21 angiogenic potential was assessed in vitro. Results: After 3 h of MCAO, C21 treatment reduced infarct size and improved behavioural outcome at 24 h without affecting blood pressure. Co-administration of the AT2R antagonist (PD123319) blocked these effects. On the molecular level, C21 decreased brain haemoglobin content, down-regulated apoptotic and oxidative markers, and increased pro-survival molecules in the brain. After 90 min of MCAO, C21 treatment resulted in sustained functional improvement at 7 days, together with increased vascular density in the ischemic penumbra. In vitro, C21 showed a pro-angiogenic effect that was blocked with brain-derived neurotrophic factor neutralization. Conclusion: These findings demonstrate that a single dose of C21 is neurovascular-protective and improves stroke outcome possibly through increasing neurotrophin activity, mitigating brain inflammation, and promoting antioxidant and pro-angiogenic effects.

2 August 2014 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
TITauheed Ishrat
Tauheed Ishrat
BPBindu Pillai
Bindu Pillai
SSSahar Soliman
Sahar Soliman
Abdelrahman FoudaAbdelrahman Fouda
Abdelrahman Fouda
AKAnna Kozak
Anna Kozak
SFSusan C. Fagan
Susan C. Fagan

12 January 2016 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
Abdelrahman FoudaAbdelrahman Fouda
Abdelrahman Fouda
AAAhmed Alhusban
Ahmed Alhusban
TITauheed Ishrat
Tauheed Ishrat
BPBindu Pillai
Bindu Pillai
WEWael Eldahshan
Wael Eldahshan
SFSusan C Fagan
Susan C Fagan

14 January 2016 in Clinical Science
Verified
Journal Article
Closed access
PDF file
Abdelrahman FoudaAbdelrahman Fouda
Abdelrahman Fouda
SASandeep Artham
Sandeep Artham
Azza El-RemessyAzza El-Remessy
Azza El-Remessy
SFSusan C. Fagan
Susan C. Fagan
As our knowledge expands, it is now clear that the renin–angiotensin (Ang) system (RAS) mediates functions other than regulating blood pressure (BP). The RAS plays a central role in the pathophysiology of different neurovascular unit disorders including stroke and retinopathy. Moreover, the beneficial actions of RAS modulation in brain and retina have been documented in experimental research, but not yet exploited clinically. The RAS is a complex system with distinct yet interconnected components. Understanding the different RAS components and their functions under brain and retinal pathological conditions is crucial to reap their benefits. The aim of the present review is to provide an experimental and clinical update on the role of RAS in the pathophysiology and treatment of stroke and retinopathy. Combining the evidence from both these disorders allows a unique opportunity to move both fields forward.

13 November 2013 in Experimental & Translational Stroke Medicine
Verified
Journal Article
Open access
PDF file
Abdelrahman FoudaAbdelrahman Fouda
Abdelrahman Fouda
AKAnna Kozak
Anna Kozak
AAAhmed Alhusban
Ahmed Alhusban
JSJeffrey A Switzer
Jeffrey A Switzer
SFSusan C Fagan
Susan C Fagan
Exogenous administration of the anti-inflammatory cytokine, interleukin 10 (IL-10), is known to promote neuroprotection and mitigate neuroinflammation after ischemia. However, endogenous expression and localization of IL-10 and its receptor (IL-10R) in the post-ischemic brain are still to be elucidated. In this investigation we aimed at determining the temporospatial expression of IL-10 in the rat brain relative to its systemic levels after ischemic stroke.

1 June 2014 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
SSSahar Soliman
Sahar Soliman
TITauheed Ishrat
Tauheed Ishrat
APAnilkumar Pillai
Anilkumar Pillai
PSPayaningal R Somanath
Payaningal R Somanath
AEAdviye Ergul
Adviye Ergul
SFSusan C. Fagan
Susan C. Fagan
Angiogenesis is a key component of recovery after stroke. Angiotensin II receptor blocker (ARB) treatment improves neurobehavioral outcome and is associated with enhanced angiogenesis after stroke. The purpose of this study is to investigate the temporal pattern of the ARB proangiogenic effect in the ischemic brain and its association with vascular endothelial growth factors VEGF-A and VEGF-B. Wistar rats were exposed to 90-minute middle cerebral artery occlusion and treated with candesartan (1 mg/kg) at reperfusion. The proangiogenic potential of the cerebrospinal fluid was determined at 8, 24, 48, and 72 hours using an in vitro Matrigel tube formation assay. In addition, the expression of VEGF-A and VEGF-B was measured in brain homogenates using Western blotting at the same time points. A single candesartan dose induced a prolonged proangiogenic effect and a prolonged upregulation of VEGF-A and VEGF-B in vivo. In the ischemic hemisphere, candesartan treatment was associated with stabilization of hypoxia-inducible factor-1α and preservation of angiopoietin-1. The effect of ARB treatment on endothelial cells was studied in vitro. Our results identified brain endothelial cells as one target for the action of ARBs and a source of the upregulated VEGF-A and VEGF-B, which exerted an autocrine angiogenic response, in addition to a paracrine neuroprotective effect. Taken together, this study highlights the potential usefulness of augmenting the endogenous restorative capacity of the brain through the administration of ARBs.